These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 21972030)

  • 21. Coupled modelling of tumour angiogenesis, tumour growth and blood perfusion.
    Cai Y; Xu S; Wu J; Long Q
    J Theor Biol; 2011 Jun; 279(1):90-101. PubMed ID: 21392511
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improving T-cell immunotherapy for melanoma through a mathematically motivated strategy: efficacy in numbers?
    Kronik N; Kogan Y; Schlegel PG; Wölfl M
    J Immunother; 2012; 35(2):116-24. PubMed ID: 22306899
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mathematical modelling of flow through vascular networks: implications for tumour-induced angiogenesis and chemotherapy strategies.
    McDougall SR; Anderson AR; Chaplain MA; Sherratt JA
    Bull Math Biol; 2002 Jul; 64(4):673-702. PubMed ID: 12216417
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
    O'Malley BW; Li D; McQuone SJ; Ralston R
    Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rationale of combination chemotherapy based on preclinical experiments.
    Goldin A
    Cancer Chemother Rep 3; 1973 Mar; 4(2):189-98. PubMed ID: 4580857
    [No Abstract]   [Full Text] [Related]  

  • 27. A mathematical approach to study combined effects of toxicants in vitro: evaluation of the Bliss independence criterion and the Loewe additivity model.
    Goldoni M; Johansson C
    Toxicol In Vitro; 2007 Aug; 21(5):759-69. PubMed ID: 17420112
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy.
    Dredge K; Marriott JB; Todryk SM; Dalgleish AG
    Cancer Immunol Immunother; 2002 Nov; 51(10):521-31. PubMed ID: 12384803
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modeling oxaliplatin drug delivery to circadian rhythms in drug metabolism and host tolerance.
    Clairambault J
    Adv Drug Deliv Rev; 2007 Aug; 59(9-10):1054-68. PubMed ID: 17707544
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy.
    Baxevanis CN; Perez SA; Papamichail M
    Cancer Immunol Immunother; 2009 Mar; 58(3):317-24. PubMed ID: 18704409
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mixed immunotherapy and chemotherapy of tumors: feedback design and model updating schemes.
    Chareyron S; Alamir M
    J Theor Biol; 2009 Jun; 258(3):444-54. PubMed ID: 18655792
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cytotoxic effects of the combination of a new nitrosourea, fotemustine, combined with 5-fluorouracil and folinic acid depend on the sequence of their administration].
    Fischel JL; Formento P; Berlion M; Berille J; Gioanni J; Bizzari JP; Milano G
    Bull Cancer; 1992; 79(1):81-90. PubMed ID: 1520955
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies.
    Chou TC
    Pharmacol Rev; 2006 Sep; 58(3):621-81. PubMed ID: 16968952
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mathematical modelling for the assessment of the effect of drug application delays in metronomic chemotherapy of cancer due to physiological constraints.
    Mukherjee A; Majumder D
    Biosystems; 2008 Jan; 91(1):108-16. PubMed ID: 17889991
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined chemoimmunotherapy of solid tumours: improving vaccines?
    Nowak AK; Lake RA; Robinson BW
    Adv Drug Deliv Rev; 2006 Oct; 58(8):975-90. PubMed ID: 17005292
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potentiation of anti-cancer drug activity at low intratumoral pH induced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) and its analogue benzylguanidine (BG).
    Kuin A; Aalders M; Lamfers M; van Zuidam DJ; Essers M; Beijnen JH; Smets LA
    Br J Cancer; 1999 Feb; 79(5-6):793-801. PubMed ID: 10070871
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoadjuvant cisplatin for head and neck cancer: Simulation of a novel schedule for improved therapeutic ratio.
    Marcu LG; Bezak E
    J Theor Biol; 2012 Mar; 297():41-7. PubMed ID: 22182756
    [TBL] [Abstract][Full Text] [Related]  

  • 38. On immunotherapies and cancer vaccination protocols: a mathematical modelling approach.
    Joshi B; Wang X; Banerjee S; Tian H; Matzavinos A; Chaplain MA
    J Theor Biol; 2009 Aug; 259(4):820-7. PubMed ID: 19446568
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cancer immunotherapy, mathematical modeling and optimal control.
    Castiglione F; Piccoli B
    J Theor Biol; 2007 Aug; 247(4):723-32. PubMed ID: 17543345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CombiTool--a new computer program for analyzing combination experiments with biologically active agents.
    Dressler V; Müller G; Sühnel J
    Comput Biomed Res; 1999 Apr; 32(2):145-60. PubMed ID: 10337496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.